20140146.LumB
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.440
- FATTY_ACID_METABOLISM+0.290
- MYC_TARGETS_V1+0.230
- DNA_REPAIR+0.200
- ESTROGEN_RESPONSE_EARLY+0.180
- SPERMATOGENESIS+0.170
- ESTROGEN_RESPONSE_LATE+0.140
- PROTEIN_SECRETION+0.070
- ADIPOGENESIS+0.060
- BILE_ACID_METABOLISM+0.030
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.470
- IL6_JAK_STAT3_SIGNALING-0.430
- ANGIOGENESIS-0.420
- APICAL_JUNCTION-0.410
- HEDGEHOG_SIGNALING-0.410
- INFLAMMATORY_RESPONSE-0.410
- ALLOGRAFT_REJECTION-0.390
- NOTCH_SIGNALING-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-6972-01A-11R-1949-07 | — | cohortA2 | 0.897 |
| 2 | SRR8518209 | — | C | 0.893 |
| 3 | SRR35579800 | — | B | 0.869 |
| 4 | TCGA-LL-A6FP-01A-11R-A31O-07 | — | B | 0.864 |
| 5 | TCGA-D8-A1JI-01A-11R-A13Q-07 | — | B | 0.861 |
| 6 | ERR2278863 | — | — | 0.853 |
| 7 | AUR-AFKB-TTM1-A-1-1-R-A742-41 | — | C | 0.852 |
| 8 | SRR1432321 | GTEX | — | 0.850 |
| 9 | SRR10900001 | — | — | 0.849 |
| 10 | SRR35579848 | — | B | 0.849 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.440 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.070 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.010 | Cobimetinib | — uncovered |